Compare Box Inc (BOX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Neurocrine Biosciences Inc — how do they compare? Box Inc trades at $29.3 (market cap $4.16B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.2× Box Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| BOX | NBIX | |
|---|---|---|
Market Cap | $4.16B | $17.30B |
Sector | Technology | Health |
52-Week High | $33.55 | $180.55 |
52-Week Low | $21.37 | $123.10 |
Enterprise Value | $4.71B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $29.41, up 2.69% today, near its consensus price target low of $29.00. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.09B in 2025 with net income surging to $244.62M, reflecting a robust profit margin expansion. Recent earnings beats in Q4 2025 and Q1 2026 support positive sentiment, while the company expanded Box Zones globally to enhance data governance (Business Wire, 2026-06-30).
The outlook remains favorable with a $37.00 analyst price target implying 26% upside, backed by 60.7% buy ratings. Key risks include high P/E of 45.95 suggesting premium valuation, competitive pressures in content management, and debt levels requiring monitoring. Positive cash flow trends and strategic expansions provide growth catalysts, but investors should weigh valuation concerns against earnings momentum.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
